

NOW AVAILABLE for patients with **moderate to severe** Alzheimer's disease

NEW ARICEPT® 23 mg tablet

DOSAGE	PACKAGE SIZE	NDC
23 mg/day 	Bottles of 30	62856-247-30
	Bottles of 90	62856-247-90

Tablet is shown at actual size.



Storage

☞ Tablets should be stored at controlled room temperature, 15°C to 30°C (59°F to 86°F)

Indication

ARICEPT is indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease (AD).

The indicated doses are: 5 mg/day for mild to moderate AD; 10 mg/day for mild, moderate, and severe AD; and 23 mg/day for moderate to severe AD.

The recommended starting dose of ARICEPT is 5 mg/day. A dose of 10 mg/day can be administered once patients have been on 5 mg/day for 4 to 6 weeks; 23 mg/day can be administered once patients have been on 10 mg/day for at least 3 months.

IMPORTANT SAFETY INFORMATION

ARICEPT, a cholinesterase inhibitor, has the potential to increase gastric acid secretion. Patients at risk for developing ulcers, including those receiving concurrent NSAIDs, should be monitored closely for gastrointestinal bleeding.

Syncope episodes have been reported in association with the use of ARICEPT.

ARICEPT should be used cautiously in patients undergoing anesthesia and with certain preexisting conditions, such as bradycardia, seizure disorder, asthma/chronic obstructive pulmonary disease, and bladder outflow disorders, as cholinesterase inhibitors have the potential to exacerbate these conditions.

The use of ARICEPT 23 mg/day is associated with weight loss. Consideration should be given when prescribing ARICEPT 23 mg/day to patients of lower weight.

In clinical trials, the most common adverse events seen with ARICEPT were nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia. The incidence of nausea and vomiting was markedly greater in patients taking ARICEPT 23 mg/day vs patients continued on ARICEPT 10 mg/day.

Please consult accompanying full prescribing and patient information.



ARICEPT® is a registered trademark of Eisai Co., Ltd.
AAR00257 © 2010 Eisai Inc. and Pfizer Inc.
All rights reserved. Printed in USA/July 2010




Aricept[®]
donepezil HCl tablet
23 mg